Parameter
| Biomarker | Fecal lactoferrin (SL) | Full name | Fecal lactoferrin | Molecular Type | Protein (iron-binding glycoprotein) |
|---|---|---|---|---|---|
| Molecular Formula | Human lactoferrin: C₆₉₀H₁₁₁₂N₁８８O₂₀₀S₄ | Molecular Weight | ~80 kDa | Core Functional Dimensions | Monitoring of intestinal mucosal damage |
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Stool (ELISA, immunochromatography, POCT kit) | ||
| Pathobiological Mechanisms | 1. It is mainly derived from neutrophil secondary granules, which are released into the intestinal lumen with the infiltration of neutrophils during intestinal inflammation, directly reflecting the degree of mucosal injury; (2) There was a significant correlation between SL and the degree of mucosal erosion and ulcer under UC endoscopy (r=0.72). When SL > 7.5μg/g, the mucosal healing rate of UC patients decreased by 50%; (3) Strong stability (tolerance to 3 times freezing and thawing), high repeatability (CV < 10%), can replace some endoscopic examination | ||||
| Clinical Availability Status | Routine clinical application | ||||
| Notes and Dynamics | 1. The Consensus on Diagnosis and Treatment of UC in 2024 recommends SL as a monitoring index for UC in remission, and SL < 2μg/g indicates stable remission. (2) Frontier research integrated SL and gut microbiota data to develop a joint prediction model of "inflammation-microbiota", and the accuracy of UC recurrence prediction reached 82% | ||||